Another bidder (BDR) revisits

Research output: Contribution to journalComment/debate

6 Citations (Scopus)

Abstract

In this issue of Blood, Gavriatopoulou and colleagues report the mature results of the European Myeloma Network (EMN)-conducted phase 2 trial evaluating the activity of bortezomib, dexamethasone, and rituximab (BDR) in treatment-naïve patients with Waldenström macroglobulinemia (WM).1 An array of combination regimens has been studied in WM, and the ever-growing list of bidders contributes to the conundrum of choosing an appropriate regimen.2

Original languageEnglish (US)
Pages (from-to)398-400
Number of pages3
JournalBlood
Volume129
Issue number4
DOIs
StatePublished - Jan 26 2017

Fingerprint

Patient treatment
Waldenstrom Macroglobulinemia
Dexamethasone
Blood
Bortezomib
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Another bidder (BDR) revisits. / Kapoor, Prashant.

In: Blood, Vol. 129, No. 4, 26.01.2017, p. 398-400.

Research output: Contribution to journalComment/debate

Kapoor, Prashant. / Another bidder (BDR) revisits. In: Blood. 2017 ; Vol. 129, No. 4. pp. 398-400.
@article{9ba734df17124eb2bc5e91602a1e0fa8,
title = "Another bidder (BDR) revisits",
abstract = "In this issue of Blood, Gavriatopoulou and colleagues report the mature results of the European Myeloma Network (EMN)-conducted phase 2 trial evaluating the activity of bortezomib, dexamethasone, and rituximab (BDR) in treatment-na{\"i}ve patients with Waldenstr{\"o}m macroglobulinemia (WM).1 An array of combination regimens has been studied in WM, and the ever-growing list of bidders contributes to the conundrum of choosing an appropriate regimen.2",
author = "Prashant Kapoor",
year = "2017",
month = "1",
day = "26",
doi = "10.1182/blood-2016-12-754523",
language = "English (US)",
volume = "129",
pages = "398--400",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Another bidder (BDR) revisits

AU - Kapoor, Prashant

PY - 2017/1/26

Y1 - 2017/1/26

N2 - In this issue of Blood, Gavriatopoulou and colleagues report the mature results of the European Myeloma Network (EMN)-conducted phase 2 trial evaluating the activity of bortezomib, dexamethasone, and rituximab (BDR) in treatment-naïve patients with Waldenström macroglobulinemia (WM).1 An array of combination regimens has been studied in WM, and the ever-growing list of bidders contributes to the conundrum of choosing an appropriate regimen.2

AB - In this issue of Blood, Gavriatopoulou and colleagues report the mature results of the European Myeloma Network (EMN)-conducted phase 2 trial evaluating the activity of bortezomib, dexamethasone, and rituximab (BDR) in treatment-naïve patients with Waldenström macroglobulinemia (WM).1 An array of combination regimens has been studied in WM, and the ever-growing list of bidders contributes to the conundrum of choosing an appropriate regimen.2

UR - http://www.scopus.com/inward/record.url?scp=85014878924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014878924&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-12-754523

DO - 10.1182/blood-2016-12-754523

M3 - Comment/debate

VL - 129

SP - 398

EP - 400

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -